Trial Profile
Phase I Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 23 Aug 2023
Price :
$35
*
At a glance
- Drugs Fostamatinib (Primary) ; Paclitaxel (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Sarcoma
- Focus Adverse reactions
- 17 Aug 2023 Planned End Date changed from 1 Oct 2023 to 1 Oct 2024.
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 10 Aug 2022 Status changed from recruiting to active, no longer recruiting.